相关实验视频

Updated: Jun 7, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

关于Fc-glycan特异性抗体-药物合物的技术,临床前和临床发展

Qiang Yang¹, Yunpeng Liu²

¹Brilliant BioConsultation Ellicott City MD 21043 USA Brilliant.BioConsult@gmail.com.

RSC medicinal chemistry

|November 21, 2024

概括

针对fc-glycan的特定抗体-药物结合物 (gsADCs) 通过使用特定的甘氨酸位点进行结合,可以改善癌症治疗. 这种方法提高了药物的同质性,药理动力学和治疗指数,在临床试验中使用了几种gsADC.

科学领域:

生物技术是生物技术.
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

抗体-药物合物 (ADC) 是一种关键的癌症治疗方式.
传统的ADC由于随机结合而面临局限性.
特定位点的结合提供了改进的ADC特性.

研究的目的:

审查Fc-糖甘特异性ADCs (gsADCs) 的发展情况.
为了突出Fc-glycan结合的优点和技术.
讨论gsADCs的临床进展.

主要方法:

对Fc-glycan特定的结合技术的审查.
对gsADCs的临床前和临床数据的分析.
讨论制造和Fc受体相互作用的考虑因素.

主要成果:

Fc-甘氨酸的结合产生了均的和水友的ADCs.
gsADCs表现出增强的药理动力学和治疗指数.
JSKN003和IBI343显示有希望的第一阶段结果,进入第三阶段.

结论:

gsADCs代表了ADC技术的重大进步.
大规模制造和Fc受体结合的挑战需要进一步的创新.
gsADCs具有巨大的潜力,可以彻底改变癌症治疗.

更多相关视频

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...